With immense of optimism and confidence, we have agreed to perform a multi-national clinical evaluation for the assessment of our first product, the miniMDR-TB® test. The product will be validated in at least seven WHO sponsored Supernational Reference Laboratories in Europe and Asia. The clinical evaluation is scheduled to start in Jan. 2017.
EMPE is excited to announce that we have established clinical consortium with premier TBnet for the clinical evaluation of their products.
It is our pleasure to announce that EMPE has received a collaborative research grant to develop a new RCA-ADT rapid detection platform for diarrhoeagenic E. coli and Vibrio Cholerae. The consortium includes University of Loughborough (UK), University of Cambridge (UK), International Centre for Diarrhoeal Disease Research (Bangladesh) and Stockholm University (Sweden).